Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Invest. 2006 Nov;116(11):2837-42.

Drug discovery in jeopardy.

Author information

1
Department of Pharmacology, University of California San Diego, San Diego, California 92067, USA. pedrocuatrecasas@znet.com

Abstract

Despite striking advances in the biomedical sciences, the flow of new drugs has slowed to a trickle, impairing therapeutic advances as well as the commercial success of drug companies. Reduced productivity in the drug industry is caused mainly by corporate policies that discourage innovation. This is compounded by various consequences of mega-mergers, the obsession for blockbuster drugs, the shift of control of research from scientists to marketers, the need for fast sales growth, and the discontinuation of development compounds for nontechnical reasons. Lessons from the past indicate that these problems can be overcome, and herein, new and improved directions for drug discovery are suggested.

PMID:
17080187
PMCID:
PMC1626142
DOI:
10.1172/JCI29999
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for American Society for Clinical Investigation Icon for PubMed Central
    Loading ...
    Support Center